PCSK9 and atherosclerosis: After describing the effects of mutations in the PCSK9 gene on LDL-C and ASCVD, therapeutic approaches including monoclonal antibodies (e.g., alirocumab, evolocumab) and small interfering ribonucleic acid (siRNA) (e.g., inclisiran) were developed to modulate and inhibit PCSK9.